Clinical trial
Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative…
NCT00383994 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00383994 |
|---|---|
| Title | Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation |
| Official title | Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lymphoma, Leukemia, Transplantation, Stem Cell, Lymphoid Malignancies, Disorder Related to Transplantation |
| Intervention type | Biological, Drug |
| Interventions | GM-CSF, Rituximab, NK Cell Infusion |
| Enrollment | 6 |
| Start date | Sep 1, 2006 |
| Primary completion | Jul 22, 2019 |
| Completion | Jul 22, 2019 |
| First posted | Oct 4, 2006 |
| Last update posted | Jul 31, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: